focus -WSS

focus

author：fashion 2025-09-27 21:12:50 Page View：675

Adam's take main illustration — Molly Ferguson/STAT

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

focus

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Industry veterans launch new biotech VC with $310M

AdobeThreebiotechVCveterans,includingoneoftheco-foundersofradiopharmasuccessstoryRayzeBio,arelaunchi

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

For Medicare Advantage, Democrats want stronger protections around AI

Sen.ElizabethWarren(D-Mass.)KentNishimura/GettyImagesSenateDemocratsonThursdaysaidMedicareshouldtake

focus

knowledge

focus

For Medicare Advantage, Democrats want stronger protections around AI